StockTipsArenaBeta

BUY Cohance Lifesciences Limited — BOB Capital Markets

BUYCohance Lifesciences Limited
Cohance Lifesciences share price target & all analyst calls

byBOB Capital MarketsHorizon: NA (inferred 1 year)13 Feb 2026via Institutional / Brokerage Research

Entry₹315.6Inferred
Target₹414
Total upside +31.18% (call closed)
Stop lossNot given
Exit₹41427 Apr 2026, 12:04 pm
Target hit+31.18%0.00%upside left
Follow BOB Capital Markets for new calls(63% target hit, 358 closed calls)Get alertsWatch COHANCE for new buy/sell callsGet alertsSee 4 active Long-term calls on COHANCESee 274 active Long-term picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

As of 25 Oct, 10:51 pm IST
2 supporting1 opposing
Supports the BUY call (2)

Umang Vohra, former Cipla CEO, appointed Executive Chairman & Group CEO of Cohance Lifesciences, effective May 1 & May 20, 2026. He succeeds Vivek Sharma, who will serve as an advisor.

NSE · Press Release·27 Apr · today

(opens in new tab)

1 other SEBI-registered advisor has an active long-term BUY call on this stock

Advisor consensus · same horizon·29 May · 11mo ago

Neutral / worth noting (0)

Nothing found in this tip’s window yet.

Weighs against the BUY call (1)

Cohance Lifesciences Limited's Executive Chairman and Director, Mr. Vivek Sharma, has resigned effective April 30, 2026. He will transition to a Special Advisor role for nine months. The company also

NSE · Outcome of Board Meeting·27 Apr · today

(opens in new tab)

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Cohance Lifesciences

All analyst calls on Cohance Lifesciences

More from BOB Capital Markets

Every call and its outcome